clinical trial · NCT07209462
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Fragile X SyndromeLow dose of MRM-3379Middle Dose of MRM-3379High dose of MRM-3379PlaceboLow dose of MRM-3379 Open-Label
brief summary
This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to \<16 will receive open-label MRM-3379. All participants will participate for 12 weeks of treatment. The study is also intended as a proof-of-concept investigation to evaluate whether MRM-3379 can improve FXS symptoms
started
Nov 22, 2025
primary completion
Oct 1, 2027
completion
Oct 1, 2027
last updated
Jun 4, 2026
official title
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol